Screening and exploration of neoadjuvant "de-escalation" therapy for early breast cancer.

ABSTRACT:

Background

Neoadjuvant therapy for breast cancer improves the prognosis of high-risk patients. However, whether pathological completed response (pCR) can be used as a surrogate endpoint for de-escalation therapy in patients who are relatively sensitive to treatment remains to be elucidated.

Methods

We retrospectively reviewed 143 breast cancer patients, with clinical stage (cStage) II-IIIA who received neoadjuvant chemotherapy and achieved pCR in a short time (within 16 weeks) from 2012 to 2022. The prognosis of patients was analysed using the Kaplan-Meier method, Cox proportional hazards regression models to identify independent clinicopathologic factors affecting prognosis.

Results

The median follow-up period was 47 months, the overall 4-year disease-free survival (

SUBMITTER: Zhang N 

PROVIDER: S-EPMC11975863 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature